Molecular Templates, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $22.3M | $13.3M |
| Operating income | −$10.5M | −$88.9M | −$80.1M | −$100.8M | −$70.4M | −$31.0M |
| Net income | −$8.1M | −$92.7M | −$83.0M | −$104.9M | −$69.4M | −$30.3M |
| Total assets | $35.4M | $97.5M | $192.4M | $139.9M | $4.2M | $140.2M |
| Total liabilities | $31.2M | $112.7M | $126.7M | $80.5M | $4.7M | $39.3M |
| Equity | $4.2M | −$15.1M | $65.7M | $59.3M | $103.0M | $100.9M |
| EPS (diluted) | $-1.80 | $-1.65 | $-1.50 | — | — | — |
| Shares out. | 56.4M | 56.3M | 56.1M | 45.6M | 36.7M | 27.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- —
- Net margin
- —
- Return on equity
- −192.9%
- Return on assets
- −23.0%
- Return on capital (ROCE)
- −57.9%
- Liabilities / assets
- 88.1%
- Debt / equity
- 7.40×
- Book value / share
- $0.07
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -43.67distress
- Accruals / assets
- 95.2%high accruals
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 0 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 15, 2024
- NT 10-Qmissed a reporting deadline ↗May 12, 2020
- NT 10-Qmissed a reporting deadline ↗May 16, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Silverarc Capital Management, LlcPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Bankruptcy or receivership · New financial obligation · Debt acceleration / triggering eventApr 24, 2025
- Entered a material agreement · New financial obligation · Modified shareholder rightsFeb 26, 2025
- Director / officer change · Other material eventJan 2, 2025
- Delisting / listing-standard noticeDec 19, 2024
- Shareholder voteDec 4, 2024
- Director / officer changeDec 4, 2024
- Delisting / listing-standard notice · Shareholder vote · Other material eventNov 26, 2024
- Costs from exit or disposalOct 11, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.